Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/158497
Title: | mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer |
Author: | Zabala Letona, Amaia Arruabarrena-Aristorena, Amaia Martín Martín, Natalia Fernández Ruiz, Sonia Sutherland, James David Clasquin, Michelle Tomas Cortazar, Julen Jimenez, Jose Torres, Inés de Quang, Phong Ximénez Embún, Pilar Bago, Ruzica Ugalde Olano, Aitziber Loizaga Iriarte, Ana Lacasa-Viscasillas, Isabel Unda Urzaiz, Miguel Torrano, Verónica Cabrera, Diana van Liempd, Sebastiaan M. Cendon, Ylenia Castro, Elena Murray, Stuart Revandkar, Ajinkya Alimonti, Andrea Zhang, Yinan Barnett, Amelia Lein, Gina Pirman, David Cortazar, Ana Rosa Arreal, Leire Prudkin, Ludmila Astobiza, Ianire Valcarcel Jimenez, Lorea Zuñiga García, Patricia Fernandez-Dominguez, Itziar Piva, Marco Caro Maldonado, Alfredo Sánchez Mosquera, Pilar Castillo Martin, Mireia Serra Elizalde, Violeta Beraza, Naiara Gentilella, Antonio Thomas, George Azkargorta, Mikel Elortza, Felix Farràs, Rosa Olmos, David Efeyan, Alejo Anguita, Juan Muñoz, Javier Falcón Pérez, Juan Manuel Barrio, Rosa Macarulla, Teresa Mato, José M. Martínez Chantar, Maria Luz Cordon Cardo, Carlos Aransay, Ana M. Marks, Kevin Baselga Torres, Josep, 1959- Tabernero Caturla, Josep Nuciforo, Paolo Manning, Brendan D. Marjon, Katya Carracedo, Arkaitz |
Keywords: | Proteïnes quinases Càncer de pròstata Protein kinases Prostate cancer |
Issue Date: | 6-Jul-2017 |
Publisher: | Nature Publishing Group |
Abstract: | Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation1,2. Here we show that mechanistic target of rapamycin complex 1 (mTORC1) regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. By using integrative metabolomics in a mouse model3 and human biopsies4 of prostate cancer, we identify alterations in tumours affecting the production of decarboxylated S-adenosylmethionine (dcSAM) and polyamine synthesis. Mechanistically, this metabolic rewiring stems from mTORC1-dependent regulation of S-adenosylmethionine decarboxylase 1 (AMD1) stability. This novel molecular regulation is validated in mouse and human cancer specimens. AMD1 is upregulated in human prostate cancer with activated mTORC1. Conversely, samples from a clinical trial with the mTORC1 inhibitor everolimus5 exhibit a predominant decrease in AMD1 immunoreactivity that is associated with a decrease in proliferation, in line with the requirement of dcSAM production for oncogenicity. These findings provide fundamental information about the complex regulatory landscape controlled by mTORC1 to integrate and translate growth signals into an oncogenic metabolic program. |
Note: | Versió postprint del document publicat a: https://doi.org/10.1038/nature22964 |
It is part of: | Nature, 2017, vol. 547, p. 109-113 |
URI: | https://hdl.handle.net/2445/158497 |
Related resource: | https://doi.org/10.1038/nature22964 |
ISSN: | 0028-0836 |
Appears in Collections: | Articles publicats en revistes (Ciències Fisiològiques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
672985.pdf | 4.8 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.